# Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Study · id `cardio:ct-nct02429258` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02429258](<https://clinicaltrials.gov/study/NCT02429258>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02429258

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 226 participants.

## Technical summary

Registry record NCT02429258. Randomized; triple masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2015-10 (actual). Results posted on 2017-04-11.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 226 participants (enrolled count; ClinicalTrials.gov record NCT02429258, source copy `cardio:ctgov-nct02429258-2017-06-14`, retrieved 2026-10-26)
- Start date: 2015-05 (registry gives no type) (ClinicalTrials.gov record NCT02429258, source copy `cardio:ctgov-nct02429258-2017-06-14`, retrieved 2026-10-26)
- Primary completion: 2015-10 (actual) (ClinicalTrials.gov record NCT02429258, source copy `cardio:ctgov-nct02429258-2017-06-14`, retrieved 2026-10-26)
- Completion: 2015-10 (actual) (ClinicalTrials.gov record NCT02429258, source copy `cardio:ctgov-nct02429258-2017-06-14`, retrieved 2026-10-26)
- Results first posted: 2017-04-11 (ClinicalTrials.gov record NCT02429258, source copy `cardio:ctgov-nct02429258-2017-06-14`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02429258, source copy `cardio:ctgov-nct02429258-2017-06-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02429258-2017-06-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
- Condition: Type II Diabetes
- Intervention (Drug): Farxiga
- Intervention (Drug): Placebo
- Intervention (Drug): Metformin
- Intervention (Drug): Insulin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (Farxiga) (`cardio:farxiga`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial (`cardio:pubmed-30222367`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6839c821526250c5c5ca08b3171108b5d71c6a489022af1b889e00d839b65840
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
